Right to Treat Act

Legislative Summary: S. 1830 - Right to Treat Act

Overview

The Right to Treat Act is a legislative proposal designed to limit the authority of federal agencies over the practice of medicine and to protect the ability of healthcare providers to prescribe FDA-approved drugs for "off-label" uses. The bill seeks to shift the regulatory focus away from the clinical interaction between doctors and patients, asserting that the federal government should not regulate the practice of medicine itself.

Key Provisions

1. Limitation of Federal Regulatory Authority

The bill explicitly strips federal agencies—specifically naming the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC)—of the authority to regulate the practice of medicine.

2. Protection of "Off-Label" Prescribing

The Act prohibits any federal law, rule, regulation, or policy from restricting the prescription or disbursement of drugs for unapproved (off-label) uses, provided that:
* The drug is already approved by the FDA, or
* The drug is available under section 561B of the Federal Food, Drug, and Cosmetic Act (which typically refers to expanded access/compassionate use programs).

3. Explicit Exceptions (Rule of Construction)

To ensure the bill is not used to legalize certain procedures, the Act contains a "Rule of Construction." It explicitly states that this law does not override or affect any existing federal restrictions regarding:
* Abortion
* Assisted suicide, euthanasia, or mercy killing
* Coercive family planning
* Female genital mutilation
* Gender transition medical interventions

Impact and Affected Parties

• Healthcare Providers: Physicians and practitioners would have greater legal protection to prescribe approved medications for uses not specifically listed on the FDA-approved label without fear of federal regulatory interference.
• Federal Agencies: The FDA, NIH, and CDC would see a significant reduction in their oversight capabilities regarding how medicine is practiced in a clinical setting.
• Patients: Patients may gain broader access to off-label treatments, though the bill does not change the safety or efficacy standards for the drugs themselves.

Procedural Status

• Introduced: May 21, 2025
• Committee: Referred to the Committee on Health, Education, Labor, and Pensions.
• Recent Activity: Committee hearings were held on March 19, 2026.